Alex Therapeutics
Alex Therapeutics
We build clinically validated digital companion apps and digital therapeutics that help people with complex conditions — especially cancer and rare diseases — manage treatments, symptoms and mental health. Our solutions combine evidence-based psychological interventions (CBT-informed), user-centred design and AI to improve adherence and patient outcomes.
What we do
We partner with pharmaceutical companies to design, develop and scale indication-specific therapy companions and Software as a Medical Device (SaMD) products. Our offerings include customizable therapy companions, clinically proven digital therapies, and regulated product development guided by regulatory and market-access expertise.
Founded in 2018 by John Drakenberg and Oliver Fleetwood, Alex Therapeutics grew with early product and engagement expertise (early funding from King) and now operates with a multidisciplinary team of 20+ psychologists, engineers, designers and regulatory specialists across the EU and US. Notable collaborations include work with Pfizer and other life sciences partners and products such as Almee™.
Core capabilities:
- Therapy companions and patient-facing apps to support medication adherence and mental health
- Design and delivery of evidence-based digital therapeutics (SaMD)
- Clinical validation and randomized controlled trials
- Regulatory, market access and commercialization support for pharma partners